Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03075449
Other study ID # 527.87
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 19, 2016
Est. completion date December 21, 2016

Study information

Verified date March 2020
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will describe the current medical care given to men who discuss their lower urinary tract symptoms with a HCP. It will document the primary reasons for the visit, the baseline characteristics of these men, the treatment received, and the practice patterns of specifically a primary care physician managing these patients.


Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date December 21, 2016
Est. primary completion date December 21, 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 100 Years
Eligibility Inclusion criteria:

- Males, aged =18 years old.

- Having had discussion of urinary symptoms with their PCP between 15 days and 12 months prior to the date of the phone interview.

- Able to read, speak and understand English.

- Willing to provide informed consent for study participation, authorize the release of their previous 12-month medical records from their PCP for review and de-identified data entry by Mapi into an electronic study database.

Exclusion criteria:

- Reported during screening that they had had their first-ever discussion of urinary symptoms with PCP within the 14 days prior to the date of the phone interview.

- Participation in a clinical research study that evaluated urinary symptoms in the past 12 months.

- Self-reported history of colorectal, bladder or prostate cancer.

- Self-reported neurologic disorders that affect bladder function, e.g., neurogenic bladder disorders due to spinal cord injury/disease, multiple sclerosis, Parkinsons disease.

- Self-reported history of radiation therapy to the lower abdominal and/or pelvic region.

Study Design


Locations

Country Name City State
United States 527.87.10001 Boehringer Ingelheim Investigational Site Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records The percentage of men who have been given at least one prescription medication for urinary symptoms.
This included any medications prescribed by PCP for urinary symptoms according to medical records within 12 months prior to telephone survey as described below:
Medications already prescribed by PCP for urinary symptoms prior to the 1st visit/contact for urinary symptoms within 12 months prior to telephone survey.
Medications newly prescribed by PCP upon visit(s)/contact(s) for urinary symptoms within 12 months prior to telephone survey (i.e., medications prescribed for urinary symptoms on or after the 1st visit/contact).
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men Who Received a Medical Diagnosis for Their Urinary Symptoms, as Recorded in Their Medical Records. The percentage of men who received a medical diagnosis for their urinary symptoms, as recorded in their medical records.
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men With a Diagnostic Testing Procedure Ordered or Performed Specifically for Their Urinary Symptoms. The percentage of men with a diagnostic testing procedure ordered or performed specifically for their urinary symptoms.
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men Diagnosed With LUTS/BPH (Enlarged Prostate). The percentage of men diagnosed with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) (enlarged prostate).
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men Referred to a Urologist for Their Urinary Symptoms. The percentage of men referred to a urologist for their urinary symptoms.
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men Given a Prescription for an Alpha-blocker for Their Urinary Symptoms. The percentage of men given a prescription for an alpha-blocker for their urinary symptoms.
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Percentage of Men Given Repeat Prescriptions for Their Urinary Symptoms. The percentage of men given repeat prescriptions for their urinary symptoms.
95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
Secondary The Number of Urinary-symptom Related Visits to Their PCP During the 12 Month Period Prior to Telephone Survey Interview. The number of urinary-symptom related visits to their primary care provider (PCP) during the 12 month period prior to telephone survey interview. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A

External Links